Bioresorbable Stents

Description

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Bioresorbable Stents Market to Reach $1.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Bioresorbable Stents estimated at US$496.7 Million in the year 2022, is projected to reach a revised size of US$1.2 Billion by 2030, growing at a CAGR of 12% over the analysis period 2022-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is projected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Metal-based Bioresorbable Stents segment is readjusted to a revised 10.2% CAGR for the next 8-year period.

The Europe Market is Estimated at $213.6 Million, While Asia-Pacific is Forecast to Grow at 10.8% CAGR

The Bioresorbable Stents market in Europe is estimated at US$213.6 Million in the year 2022. Asia-Pacific is forecast to reach a projected market size of US$482.2 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2022 to 2030.

Select Competitors (Total 25 Featured) -

Abbott Laboratories, Inc.
Boston Scientific Corporation
Biotronik SE & Co. KG
Eurocor GmbH
Biosensors International Group Ltd.
Elixir Medical Corporation
InSitu Technologies, Inc.
Kyoto Medical Planning Co., Ltd.
Medinol Ltd.
Lepu Medical Technology (Beijing) Co., Ltd.
Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
Meril Life Sciences Pvt., Ltd.
Arterial Remodeling Technologies SA
iVascular S.L.U
Endocor GmbH

Product Code: MCP10697

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2022 (E)
- Coronary Artery Disease (CAD) - A Perspective
- Causes and Symptoms
- Treatment Options for Coronary Artery Disease
- Percutaneous Coronary Intervention (PCI)
- Coronary Stenting
- Types of Coronary Stents
- Bare Metal Stents (BMS)
- Drug Eluting Stents (DES)
- Bioresorbable Scaffolds
- Design and Composition of Bioresorbable Scaffolds
- Different Types of Bioresorbable Scaffolds
- Metallic Bioresorbable Scaffolds
- Polymer Bioresorbable Scaffolds
- Degradation Period of Select Bioabsorbable Materials
- Challenges
- Clinical Characteristics of Various Coronary Stents
- Other Treatment Options for Coronary Heart Disease
- Coronary Artery Bypass Grafting (CABG)
- Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
- TransMyocardial Laser Revascularization (TMR)
- Peripheral Arterial Disease: Understanding the Stealthy Peril
- Treatment for PAD
- Stenting- A Treatment Option for PAD
- BioResorbable Stents - A Prelude
- Bioresorbable Vascular Scaffolds: Advantages and Challenges
- Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
- Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
- Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
- Impact of Covid-19 and a Looming Global Recession
- 2020 Marked as a Year of Disruption & Transformation
- World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
- Impact of COVID - 19 on Coronary Stents Market
- Impact on Supply Chain
- Impact of COVID-19 Outbreak on Elective Surgeries
- Global Bioresorbable Stents Market Buckles under COVID-19 Strain
GLOBAL MARKET OVERVIEW
- Global Bioresorbable Stents Set to Witness Growth in Future
- Europe Dominates, Asia-Pacific Exhibits Fastest Growth
- CAD Constitutes the Leading Application
- Metallic Vs. Polymer-based Stents
- Bioabsorbable Metallic Stents
- Bioabsorbable Polymer Stents
- Disappointing Results by Absorb to Increase Focus on Metallic Stents
- Availability of Alternative Treatments - Hindrance to Market Growth
- Market Challenges
MARKET OUTLOOK
- Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
- The Future of BRS Technology
COMPETITION
- Select Approved Bioresorbable Scaffolds
- Select Bioresorbable Stents in Pipeline
- Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
- Recent Market Activity
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Polymeric Resorbable Scaffolds Hold a Major Market Share
- The Absorb BRS program
- Desaminotyrosine Polycarbonate-based BRS
- The FANTOM program
- Magnesium-based BRS
- The Magmaris program
- Iron-based BRS
- Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
- Global Annual Medical Cost of CVD in the United States: 2015-2030
- Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
- Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
- Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
- Rising Middle Class Population Aids Growth
- Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
- Rising Healthcare Expenditure: Opportunities in Store
- World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
- Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
- Risk of CAD in Obesity Offers Prospects for Coronary Stenting
- Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
- Diabetics at Higher Risk of Heart Diseases
- TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
- The Hypertension-Cholesterol Link to Drive Demand
- Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
- Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
- Metal Stents Vis-a-Vis Other Stents
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 2: World 8-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- TABLE 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 4: World 8-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 6: World 8-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 8: World 8-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 10: World 8-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 12: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 14: World 8-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 15: World Bioresorbable Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

EUROPE
- Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 16: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 17: Europe 8-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2023 & 2030
- TABLE 18: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 19: Europe 8-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2023 & 2030
- TABLE 20: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 21: Europe 8-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2023 & 2030
ASIA-PACIFIC
- Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 22: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 23: Asia-Pacific 8-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2023 & 2030
- TABLE 24: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 25: Asia-Pacific 8-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2023 & 2030
- TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 27: Asia-Pacific 8-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2023 & 2030
REST OF WORLD
- TABLE 28: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 29: Rest of World 8-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2023 & 2030
- TABLE 30: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 31: Rest of World 8-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2023 & 2030
- TABLE 32: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 33: Rest of World 8-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2023 & 2030

Bioresorbable Stents

Description

Table of Contents

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION